aCGH Impacts Survival in Plasma Cell PTLD

Hospices Civils de Lyon10 enrolled

Overview

Plasma-cell post-transplantation lymphoproliferative disorders (PC-PTLD) are rare monomorphic PTLD divided into plasma cell myeloma (PCM) and plasmacytoma-like lesion (PLL) PTLD. To date, there is no exhaustive published cytogenetic data on PC-PTLD. The investigators report array-based comparative genomic hybridization (aCGH) of 10 cases of PCM and PLL-PTLD.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Post-transplantation Lymphoproliferative Disorders

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * WHO classification 2008 as monomorphic PCM (plasma cell myeloma) or PLL (plasmacytoma like lesion) / PTLD (post transplantation lymphoproliferative disorders). Exclusion Criteria: * Other than PCM or PLL PTLD at diagnosis

Locations (1)

Centre hospitalier Lyon sud

Pierre-Bénite, Auvergne-Rhône-Alpes, France

Outcomes

Primary Outcomes

Genome wide array-based comparative genomic hybridization (aCGH)

Time frame: At diagnosis of PTLD, Day 0.

Secondary Outcomes

Overall survival according to aCGH complexity

Time frame: Overall survival (OS) was calculated from date of diagnosis to date of death from any cause, up to 130 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.